Zobrazeno 1 - 10
of 415
pro vyhledávání: '"Steven D Gore"'
Autor:
John Barrett, Stephen J Forman, Jeffrey S Miller, Jill Brufsky, Jorge Cortes, Marcos de Lima, Michael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, Renier J Brentjens, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, John M Pagel, Martin S Tallman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplanta
Externí odkaz:
https://doaj.org/article/be3169a0058f46c98ba6cb8af3df4024
Autor:
Amer M Zeidan, Jessica B Long, Rong Wang, Xin Hu, James B Yu, Scott F Huntington, Gregory A Abel, Sarah S Mougalian, Nikolai A Podoltsev, Steven D Gore, Cary P Gross, Xiaomei Ma, Amy J Davidoff
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0184747 (2017)
There are inconsistent and limited data regarding the risk of myeloid neoplasms (MN) among breast cancer survivors who received radiotherapy (RT) in the absence of chemotherapy. Concern about subsequent MN might influence the decision to use adjuvant
Externí odkaz:
https://doaj.org/article/462e46e11a5a4b81a8b36233ed9b6a78
Publikováno v:
PLoS Genetics, Vol 12, Iss 10, p e1006193 (2016)
For several decades, we have known that epigenetic regulation is disrupted in cancer. Recently, an increasing body of data suggests epigenetics might be an intersection of current cancer research trends: next generation sequencing, immunology, metabo
Externí odkaz:
https://doaj.org/article/2abc4b0ae61b4a57bf168791c8bce41d
Autor:
Eric Laille, Tao Shi, Guillermo Garcia-Manero, Christopher R Cogle, Steven D Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J MacBeth
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135520 (2015)
CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this two-part study, a 7-day CC-486 dosing schedule showed clinical activity, was generally well t
Externí odkaz:
https://doaj.org/article/381043cb23d64b4bb4c5ab92a2004ee8
Autor:
Nikolai A. Podoltsev, Rong Wang, Rory M. Shallis, Jessica M. Stempel, Mengyang Di, Natalia Neparidze, Amer M. Zeidan, Scott F. Huntington, Smith Giri, Sarah C. Hull, Steven D. Gore, Xiaomei Ma
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18889-18900 (2023)
Abstract Background Polycythemia vera (PV) and essential thrombocythemia (ET) are linked to increased risk of cardiovascular morbidity and mortality. In addition to the reduction in of arterial thrombotic events, statins may prevent venous thrombosis
Externí odkaz:
https://doaj.org/article/37b984a3a27e4915a681f12f7319c9f7
Autor:
Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet
Publikováno v:
Blood Advances, Vol 2, Iss 16, Pp 2063-2071 (2018)
Abstract: Hypomethylating agent (HMA) failure in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) carries a poor prognosis with limited treatment options. Although intensive, remission induction chemotherapy is often used subsequently
Externí odkaz:
https://doaj.org/article/a14081773f344b32861ce66bd97dcf79
Autor:
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres, Andrew M. Brunner, Gail J. Roboz, David P. Steensma, Vijaya R. Bhatt, Uwe Platzbecker, Thomas Cluzeau, Pedro H. Prata, Raphaël Itzykson, Pierre Fenaux, Amir T. Fathi, Alexandra Smith, Ulrich Germing, Ellen K. Ritchie, Vivek Verma, Aziz Nazha, Jaroslaw P. Maciejewski, Nikolai A. Podoltsev, Thomas Prebet, Valeria Santini, Steven D. Gore, Rami S. Komrokji, Amer M. Zeidan
Publikováno v:
Blood Advances, Vol 2, Iss 14, Pp 1765-1772 (2018)
Abstract: Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes assoc
Externí odkaz:
https://doaj.org/article/a5a59ecccd024d588117d21e7d6e571f
Autor:
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Publikováno v:
Blood Advances, Vol 2, Iss 8, Pp 923-932 (2018)
Abstract: Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an
Externí odkaz:
https://doaj.org/article/486ed8a5f054402fbec21f16b3f0cd0a
Autor:
Gregory A. Abel, Donnie Hebert, Cecilia Lee, Dana E. Rollison, Nancy Gillis, Rami S. Komrokji, James M Foran, Jane Jijun Liu, Tareq Al Baghdadi, H. Joachim Deeg, Steven D Gore, Wael Saber, Steffanie H Wilson, Michael Otterstatter, Jason Thompson, Christine Borchert, Eric Padron, Amy DeZern, David Cella, Mikkael A. Sekeres
Publikováno v:
Blood Advances.
Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with myelodysplastic syndromes (MDS) and other cytopenic states; however, the heterogeneous composition of these diseases has limited our understanding of thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd3bb71211bf42d947086bb8bd9d3b49
https://doi.org/10.1182/bloodadvances.2022009000
https://doi.org/10.1182/bloodadvances.2022009000
Autor:
Ana Acuña-Villaorduña, Joaquina Celebre Baranda, Jessica Boehmer, Lola Fashoyin-Aje, Steven D. Gore
Publikováno v:
American Society of Clinical Oncology Educational Book.
The mismatch between the study populations participating in oncology clinical trials and the composition of the targeted cancer population requires urgent amelioration. Regulatory requirements can mandate that trial sponsors enroll diverse study popu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f58b77ef8fad8736e0e8c074050d6b40
https://doi.org/10.1200/edbk_389838
https://doi.org/10.1200/edbk_389838